Trials / Completed
CompletedNCT00036036
Study of CP-461 in Patients With Advanced Renal Cell Cancer
Phase II Study of CP-461 in Patients With Advanced Renal Cell Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (planned)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy of CP-461 given twice-daily orally in locally advanced or metastatic renal cell cancer and to evaluate the safety profile of CP-461 in this patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CP-461 |
Timeline
- Start date
- 2001-07-01
- Completion
- 2003-07-01
- First posted
- 2002-05-08
- Last updated
- 2011-10-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00036036. Inclusion in this directory is not an endorsement.